Introduction
============

Colon cancer accounts for the third highest incidence of cancer in the world, and its mortality rate is also increasing ([@b1-mmr-22-02-0620]). Previous studies have revealed that a family or personal history of colorectal cancer, colorectal polyps or chronic inflammatory bowel disease are the most common risk factors for colorectal cancer ([@b2-mmr-22-02-0620]--[@b4-mmr-22-02-0620]). Despite the development of early diagnostic techniques, more than 25% of patients present with metastases when they are diagnosed ([@b5-mmr-22-02-0620]). Notably \~50% of patients with colon cancer will exhibit recurrence and succumb to the disease within 5 years; although chemotherapy and targeted therapy have significantly improved the efficacy of treatment, the internal mechanism underlying colon cancer tumorigenesis has yet to be elucidated ([@b6-mmr-22-02-0620]). Hence, it is imperative to study the molecular mechanism underlying colon cancer and identify novel biomarkers to improve the prognosis of patients with colon cancer.

The competing endogenous (ce)RNA network hypothesis was proposed by Salmena *et al* ([@b7-mmr-22-02-0620]) as early as 2011 and ceRNA represents a novel mechanism of gene expression regulation. The ceRNA hypothesis is a supplement to the traditional micro(mi)RNA regulation of RNA theory, and there is a reverse RNA to miRNA action mode, that is, ceRNAs, through miRNA response elements (MREs), compete for the same miRNAs, to regulate the expression of target genes. Recently, the molecules that influence ceRNA networks include long non-coding (lnc)RNAs, pseudogenes, circular (circ)RNAs and other molecules ([@b8-mmr-22-02-0620]--[@b10-mmr-22-02-0620]). Numerous experimental studies have supported the theory of ceRNA network regulation ([@b11-mmr-22-02-0620],[@b12-mmr-22-02-0620]). For example, *PTEN, SNHG6, lncRNA-H19* and other molecules regulate the expression of corresponding target genes and influence the occurrence and progression of cancer through their conservative 3′UTR competitive adsorption of miRNA molecules ([@b7-mmr-22-02-0620],[@b13-mmr-22-02-0620]).

In the present study, the disciplinary advantages of molecular biology and bioinformatics were integrated in order to construct a molecular regulatory network in colon cancer, with lncRNA at the core, which may provide evidence to improve understanding of the mechanism underpinning the occurrence and progression of colon cancer. Similarly, the current methodology provides a novel concept for the study of other cancer-associated mechanisms.

Materials and methods
=====================

### Data source and processing

The RNA-Seq V2 data and corresponding clinical information of patients with colon cancer were downloaded from The Cancer Genome Atlas (TCGA) data portal (<https://tcga-data.nci.nih.gov/tcga/>). Registration data from a total of 546 patients were retrieved; 75 patients were excluded because they had only clinical information and not sequencing data. Finally, 471 patients with complete clinical and sequencing information were included in the present study. Of the 471 patients, 41 had paracancerous tissues which were sequenced simultaneously. The mRNA and miRNA sequencing data were processed using R software (R version 3.5.2; <http://www.R-project.org/>), and any lncRNAs with a description from Ensembl (<https://asia.ensembl.org/index.html>) were selected for further study. The data of human miRNA-target gene interaction were retrieved from the TargetScan (<http://www.targetscan.org/vert_72/>), miRDB (<http://www.mirdb.org/>) ([@b14-mmr-22-02-0620]), PITA ([https://genie.weizmann.ac.il/pubs/mir07/mir07 \_data.html](https://genie.weizmann.ac.il/pubs/mir07/mir07 _data.html)) and miRanda databases (<http://miranda.org.uk/>), and the lncRNA-miRNA interaction data came from the miRcode (<http://www.mircode.org/>) ([@b15-mmr-22-02-0620]), StarBase (<http://starbase.sysu.edu.cn/>) and lncBase databases (<http://carolina.imis.athena-innovation.gr/diana_tools/web/index.php?r-lncbasev2%2Findex>) ([@b16-mmr-22-02-0620]). RNA-seq profile data and the clinical characteristics of colon cancer are available on open-access databases; therefore, there was no requirement for approval by the local ethics committee.

### miRNA-mRNA interactive data acquisition

The interaction data of human miRNA- target genes were downloaded from TargetScan, miRDB, PITA and miRanda databases. The miRNA-mRNA interacting pairs common to \>3 databases were selected as credible miRNA-target gene pairs. Among them, TargetScan, miRanda and PITA are miRNA-gene symbol interacting pairs, while miRDB is miRNA-refseq ID interacting pairs. Therefore, refseq ID was converted to gene symbols via the hg38 annotation file. Then, if the miRNA-mRNA interacting pair was common to \>3 databases, it was regarded as a significant miRNA-mRNA interacting pair. Finally, the interacting pairs were de-duplicated.

### miRNA-lncRNA interactive data acquisition

The human lncRNA-miRNA interaction data was downloaded from three databases (miRcode, StarBase and lncBase), and the lncRNA-miRNA interacting pairs common to \>2 databases were selected as lncRNA-miRNA interacting pairs. Finally, the repeated interacting pairs were removed.

### Data acquisition of lncRNA-mRNA expression profiles in colon cancer

The RNASeqV2 data were downloaded from TCGA database. First, the expression values of genes with the same gene name were selected as the mean value, and the lncRNA expression profile and mRNA expression profile were obtained by separating RNA.

### Construction of the ceRNA network

Using the target interacting database, it was considered that the number of shared target miRNA between lncRNA and mRNA was \>3 and the hypergeometric test false discovery rate (FDR) \<0.01 was the cutoff used to identify potential lncRNA-mRNA ceRNA interacting pairs. The Spearman correlation coefficient of potential lncRNA-mRNA ceRNA pairs was calculated using the lncRNA and mRNA expression profile of colon cancer. An R \>0, adjusted P-value \<0.01, lncRNA-mRNA relationship combined with its shared miRNA constituted a competitive endogenous RNA network of lncRNA-miRNA-mRNA in colon cancer.

### Analysis of ceRNA network properties

Cytoscape was used for ceRNA network presentation ([@b17-mmr-22-02-0620]), and Molecular Complex Detection (MCODE) was used to identify four modules in the ceRNA network ([@b17-mmr-22-02-0620]). The topological properties of the network were analyzed (degree distribution, clustering coefficient and hub analysis), in which hub miRNA and hub lncRNA were selected as the core regulatory factors of colon cancer, and hub mRNA was selected as the core gene of colon cancer. Then, the random walk algorithm was used to mine the function factor (lncRNA/miRNA/mRNA) in the ceRNA network. Furthermore, enrichR was used to analyze the function and pathway of the genes ([@b18-mmr-22-02-0620]). Finally, hub mRNA and lncRNA were selected for survival analysis using the UALCAN database (<http://ualcan.path.uab.edu/index.html>) to verify that whether they could be used as a prognostic biomarker of colon cancer ([@b19-mmr-22-02-0620]).

### Identifying the lncRNA-miRNA-mRNA regulatory axis of colon cancer from extracted lncRNA-miRNA-mRNA interaction pairs using GEO datasets

GEPIA (<http://gepia.cancer-pku.cn/>) was used to analyze the ceRNA interacting pairs extracted from a colon cancer dataset ([@b20-mmr-22-02-0620]). Person correlation analysis was conducted on lncRNA and mRNA, to obtain the most positive correlation between lncRNA and mRNA relationship pairs. Next, LncACTdb 2.0 (<http://www.bio-bigdata>) was used to verify the regulatory association between lncRNA and miRNA that had been validated by relevant experiments ([@b21-mmr-22-02-0620]), and finally the GSE26334 dataset was used to verify the regulatory association between miRNA and mRNA ([@b22-mmr-22-02-0620]). The expression of mRNAs, lncRNAs and miRNAs in LoVo colon cancer lines was determined using R and visualized using GGPLOT2 3.1.0 (<https://cran.r-project.org/web/packages/ggplot2/index.html>).

### Target set of core regulators and functional enrichment analysis of core genes

The target genes (target set) of the core regulatory factors of top 10 were screened, and the function and pathway enrichment of the target genes were analyzed using enrichR. Then, enrichR was used to analyze the function and pathway of core genes in colon cancer.

### Drug design

The core genes of colon cancer were combined with all the drugs on Drugbank5.0 (<https://www.drugbank.ca>) ([@b23-mmr-22-02-0620]), and significance analysis was performed using a hypergeometric test to identify the drugs that may have therapeutic effect on colon cancer.

### Statistical analysis

Student\'s t test was used to estimate the significance of difference in gene expression levels between groups. The t-test was performed using a PERL script with Comprehensive Perl Archive Network (CPAN) module 'Statistics: T Test'.

Available TCGA patient survival data were used for Kaplan-Meier survival analyses and to generate overall survival plots. The P-value obtained from log-rank test was used to indicate statistical significance of survival correlation between groups ([@b19-mmr-22-02-0620]). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Characteristics of the subjects included in the study

The detailed clinical and pathological characteristics of all the 546 colon cancer patients downloaded from TCGA are listed in [Table I](#tI-mmr-22-02-0620){ref-type="table"}.

### Screening miRNA-mRNA interaction pairs

The human miRNA-target gene interaction data were downloaded from four databases (TargetScan, miRDB, PITA and miRanda). If the miRNA-mRNA interacting pair appeared in \>3 databases, it was included as a miRNA-mRNA interacting pair. As a result, 160,345 miRNA-mRNA interacting pairs were selected.

### Screening lncRNA-miRNA interaction pairs

The human lncRNA-miRNA interaction data was downloaded from three databases including miRcode, StarBase, lncBase, and the lncRNA-miRNA interacting pairs that appeared in more than two databases were selected as lncRNA-miRNA interacting pairs. Finally, 3,158 lncRNA-miRNA interacting pairs were obtained.

Construction of the ceRNA network
---------------------------------

### Identification of candidate ceRNA interacting pairs

Combined with the miRNA-mRNA interacting pair and lncRNA-miRNA interacting pair data, if each pair of lncRNA and mRNA sharedthe same miRNA, the lncRNA and mRNA were connected as an interacting pair. Using the R package, the hypergeometric test was applied to calculate the significance of association between lncRNA and mRNA pairs and miRNAs for each pair of lncRNA and mRNA. The parameters were as follows: Q, the number of miRNAs shared by the lncRNA and mRNA to be tested; k, number of miRNAs interacting with the gene to be tested; m, number of miRNAs interacting with the lncRNA to be tested; and n, total number of miRNAs minus the number of miRNAs to be tested. lncRNA-mRNA interacting pairs with the number of shared target miRNA \>3 and FDR \<0.01 between lncRNAs and mRNAs were selected as potential ceRNA interacting pairs. Eventually, 28,668 potential ceRNA interactions were obtained.

### Acquisition of the candidate ceRNA interaction pairs

The Spearman correlation coefficient of each potential lncRNA-mRNA ceRNA pair was calculated using the lncRNA and mRNA expression profile in colon cancer. If R\>0, the lncRNA-mRNA association of P-adjusted \<0.01 was identified as a ceRNA network of lncRNA-mRNA in colon cancer. Finally, a total of 6,933 colon cancer lncRNA-miRNA-mRNA interaction pairs and 1,258 colon cancer lncRNA-mRNA interaction pairs were identified.

### Display of the ceRNA network and analysis of topological properties in colon cancer

Cytoscape was utilized to demonstrate the colon cancer ceRNA network (lncRNA-miRNA-mRNA), as displayed in [Fig. 1](#f1-mmr-22-02-0620){ref-type="fig"}. The binary network (lncRNA-mRNA) is shown in [Fig. 2](#f2-mmr-22-02-0620){ref-type="fig"}.

In the present study, the topological properties of the network were analyzed in the network shown in [Fig. 1](#f1-mmr-22-02-0620){ref-type="fig"}. The miRNA with a degree \>10 was selected as the hub miRNA, the lncRNA with a degree \>10 was selected as the hub lncRNA and the mRNA with a degree \>10 was selected as the hub mRNAs. Finally, a total of 17 hub lncRNAs, 87 hub miRNAs and 144 hub genes of colon cancer were included ([Table SI](#SD1-mmr-22-02-0620){ref-type="supplementary-material"}). MCODE was used to identify four modules in the ceRNA network, and the module diagram is presented in [Figs. S1-4](#SD1-mmr-22-02-0620){ref-type="supplementary-material"}. The random walk algorithm was used to find the important nodes in the ceRNA network. The functional enrichment analysis of the genes was as listed in [Fig. 3](#f3-mmr-22-02-0620){ref-type="fig"}.

### Screening of biomarkers associated with prognosis via survival analysis

In order to demonstrate that the expression of colon cancer-related lncRNAs was associated with the prognosis of colon cancer, the survival curve of 17 colon cancer-related lncRNAs was identified in the UALCAN database and it was revealed that 2 of these were associated with the overall survival of patients with colon cancer. The results are presented in [Fig. 4](#f4-mmr-22-02-0620){ref-type="fig"}.

Among the results, lncRNA metastasis-associated lung adenocarcinoma transcript (*MALAT1*) and lncRNA maternally expressed gene 3 (*MEG3*) were upregulated in colon cancer tissue compared with that in normal tissue ([Fig. 4A and C](#f4-mmr-22-02-0620){ref-type="fig"}), and high expression of these lncRNAs was significantly associated with poor overall survival in patients with colon cancer ([Fig. 4B and D](#f4-mmr-22-02-0620){ref-type="fig"}).

In addition, 5 out of 144 hub genes (*FURIN, NFAT, RBM12B, RRAGD* and *WIPI2*) were closely associated with overall survival of colon cancer. The upregulation of all of these genes, apart from FURIN, was associated with poor overall survival in patients with colon cancer ([Fig. 5](#f5-mmr-22-02-0620){ref-type="fig"}).

### MALAT1 is significantly upregulated, and this is correlated with downregulation of miR-129-5p and upregulation of NFAT5, in LoVo colon cancer cell lines

Using data from the GSE26334 dataset, the full transcriptome sequence of LoVo colon cancer lines was sequenced. The differential expression among mRNAs, lncRNAs and miRNAs in LoVo colon cancer lines was then compared using the Kruskal-Wallis test and visualized by R and GGPLOT2 3.10. The results indicated that the expression levels of lncRNA *MALAT1* and mRNA *NFAT5* in LoVo colon cancer lines were significantly upregulated, while miR-129-5p was significantly downregulated, with a significant difference between them (P=0.027). This result further confirmed the prediction that the *MALAT1/miR-129-5p/NFAT5* axis was significantly associated with colon cancer ([Table II](#tII-mmr-22-02-0620){ref-type="table"}; [Fig. 6](#f6-mmr-22-02-0620){ref-type="fig"}).

### Target set of core regulators and functional enrichment analysis of core genes

The target genes (target set) of the core regulatory factor (top 10 miRNAs, top10 lncRNAs) were screened, and a total of 11,814 target sets were obtained, and the function and pathway enrichment of the target set were analyzed. The results of Gene Ontology (GO) biological process (BP) enrichment analysis are shown in [Fig. 7A](#f7-mmr-22-02-0620){ref-type="fig"}, the results of GO cell components (CC) are shown in [Fig. 7B](#f7-mmr-22-02-0620){ref-type="fig"}, the enrichment analysis results of GO molecular function (MF) enrichment analysis are shown in [Fig. 7C](#f7-mmr-22-02-0620){ref-type="fig"} and the results of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis are presented in [Fig. 7D](#f7-mmr-22-02-0620){ref-type="fig"}.

Then, enrichR was used to analyze the function and pathway of 144 core genes in colon cancer. The results of GO biological process (BP) enrichment analysis are shown in [Fig. 8A](#f8-mmr-22-02-0620){ref-type="fig"}, the results of GO cell components (CC) enrichment analysis are shown in [Fig. 8B](#f8-mmr-22-02-0620){ref-type="fig"}, the results of GO molecular function (MF) enrichment analysis are shown in [Fig. 8C](#f8-mmr-22-02-0620){ref-type="fig"} and the results of KEGG pathway enrichment analysis are shown in [Fig. 8D](#f8-mmr-22-02-0620){ref-type="fig"}.

### Drug prediction of colon cancer

Drug-target relationship data was downloaded from Drugbank, which was used as the interaction background. As a result, 144 colon cancer core genes were selected as the gene set and the drugs that interact significantly with the core genes of colon cancer were calculated using the hypergeometric test. If the hypergeometric test P-value was \<0.05 and the number of interactions with the core genes of colon cancer was \>2, the drugs were predicted to be associated with colon cancer. After data preprocessing, a total of 9,484 drug-target gene pairs were selected as the background of interaction. Finally, one drug (DB12010) met the threshold values, and was revealed to be fostamatinib; the results are given in [Table III](#tIII-mmr-22-02-0620){ref-type="table"} and [Fig. 9](#f9-mmr-22-02-0620){ref-type="fig"}.

Discussion
==========

Since the hypothesis of long-chain non-coding RNAs (lncRNAs) as a competing endogenous (ce)RNA network was firstly reported in 2011, it has become a focus of tumor research ([@b7-mmr-22-02-0620]). At present, the network theory of lncRNA-miRNA-mRNA has been gradually confirmed and serves an important role in tumor research. lncRNAs are a class of non-coding products with a length of \>200 nucleotides, and account for 68% of all non-coding RNA molecules ([@b24-mmr-22-02-0620]). As an important subgroup of non-coding RNAs, lncRNAs have been confirmed to influence a wide variety of physiological functions and pathological process, such as diabetes, cardiovascular disease, tumors and other diseases ([@b25-mmr-22-02-0620]--[@b31-mmr-22-02-0620]). They serve an important role in regulating gene expression. Since the identification of the ceRNA network, a new method of molecular regulation has been considered. lncRNAs attenuate the biological function of miRNAs by sponging miRNAs with the same microRNA response element (*MRE*). As a result of the inhibitory effect, lncRNAs are capable of regulating the tumorigenesis and progression of colon cancer.

In the present study, 6,933 lncRNA-miRNA-mRNA interaction pairs were identified in colon cancer, which included 17 hub lncRNAs, 87 hub miRNAs and 144 hub colon cancer core genes. The ceRNA construction of the present study differs from previous methods of ceRNA construction based on differential expression of lncRNAs, miRNAs and mRNAs. However, the present study used multiple databases to screen trusted miRNA-mRNA interaction pairs and lncRNA-miRNA interaction pairs. The significance of lncRNA- and mRNA-shared miRNAs was calculated by using hypergeometric test for each pair of lncRNA and mRNA by using R packages, and the lncRNA-miRNA-mRNA network was successfully constructed. It was revealed that the colon cancer-associated genes identified by random walk analysis were predominantly enriched in GO terms such as 'zinc ion transport', 'nuclear transcription factor complex', 'zinc ion transmembrane transporter activity' and 'protein phosphate regulator activity', amongst others. Previous studies have indicated that zinc transporters serve a vital role in carcinogenesis and tumorigenesis ([@b32-mmr-22-02-0620]--[@b34-mmr-22-02-0620]). Similarly, protein phosphate regulator activity is associated with numerous cancer types, such as breast cancer, prostate cancer, non-small cell lung cancer and colon cancer ([@b35-mmr-22-02-0620]--[@b37-mmr-22-02-0620]). Several cancer-associated pathways including transforming growth factor β (TGF-β) signaling, extracellular matrix (ECM) receptor interaction, Ras signaling, PI3K/Akt signaling pathways, and other biological pathways have been identified to be enriched following KEGG analysis. For example, CD51 was revealed to bind TGF-β receptors and further upregulate TGF-β/mothers against decapentaplegic homolog signaling in colorectal stem cells ([@b38-mmr-22-02-0620]). In addition, the TGF-β signaling pathway, a regulator of TWIST1, enhanced stem cell properties in human colorectal cancer ([@b39-mmr-22-02-0620]). The ECM-receptor interaction signaling pathway was found to influence the progression of breast cancer ([@b40-mmr-22-02-0620]). In addition, it was reported that Twist-related protein 2 upregulated the expression of ITGA6 and CD44 which may promote cell proliferation, migration and invasiveness in human kidney cancer via the ECM-receptor interaction pathway ([@b41-mmr-22-02-0620]). Dysregulation of Wnt/β-catenin and Hedgehog/Gli signaling was found to serve a key role in colon cancer progression ([@b42-mmr-22-02-0620]). In addition, the PI3K/Akt pathway was demonstrated to participate in the activation and regulation of cell proliferation, survival, migration and angiogenesis in numerous human cancer types, including colon cancer ([@b43-mmr-22-02-0620]). The aforementioned results confirmed that the core genes identified by random walk algorithm are primarily enriched in cancer-associated pathways.

The colon cancer core genes are a subset of the target genes of colon cancer regulators, which were found to be all enriched in GO terms such as 'transcriptional regulation of RNA polymerase II promoter', 'ubiquitin protein ligase activity' and 'nucleosome', 'transport vesicles across Golgi network', and enriched in biological pathways such as 'TGF-β signaling pathway', 'ubiquitin-mediated proteolysis' and 'Wnt signaling pathway'. It may be useful to discover the function of these core genes.

lncRNAs directly serve as oncogenes or tumor suppressors via post-transcriptional regulation in the cytoplasm, and serve critical roles in several hallmarks of cancer, such as uncontrollable proliferation, evasion and metastasis ([@b44-mmr-22-02-0620]--[@b46-mmr-22-02-0620]). In the present study, the results indicated that metastasis-associated lung adenocarcinoma transcript (*MALAT1*) and maternally expressed gene 3 (*MEG3*) were two important lncRNAs influencing colon cancer, and that a high expression of *MALAT1* was associated with poor overall survival of patients with colon adenocarcinoma. *MALAT1*, an 8.5 kb lncRNA, located at 11q13, was characterized in a study of early-stage non-small cell lung cancer ([@b30-mmr-22-02-0620]). Previous studies have demonstrated that *MALAT1* may represent a good diagnostic marker in nasopharyngeal carcinoma, breast and bladder cancer ([@b47-mmr-22-02-0620]). Furthermore, *MALAT1* has been demonstrated to sponge *miR-106b-5p* to promote the invasion and metastasis of colorectal cancer via *SLAIN2* ([@b48-mmr-22-02-0620]). However, upregulation of *MEG3* may decrease the proliferation and metastasis of gastric cancer cells ([@b49-mmr-22-02-0620]). Additionally, *MEG3* was found to be significantly downregulated in acute myeloid leukemia and suppressed leukemogenesis in a p53-independent manner ([@b50-mmr-22-02-0620]). The present study indicated that high expression of *MEG3* in colon cancers was associated with poor overall survival via bioinformatic analysis. So far, to the best of the authors\' knowledge, there has been no research on the mechanism underpinning the role of *MEG3* in the tumorigenesis of colon cancer from previous experimental studies. Therefore, future studies are required to further verify its function in colon cancer.

Previous studies have indicated that tissue- and cell-type specific expression of miRNAs may exhibit either tumor-suppressive or oncogenic effects in a context-dependent manner ([@b51-mmr-22-02-0620],[@b52-mmr-22-02-0620]). Dysregulation of miRNA function is associated with an increasing number of human disease types, particularly cancer ([@b53-mmr-22-02-0620]). According to the MCODE algorithm, 4 gene modules (MCODE score ≥3) were constructed, including hub miRNAs, including hsa-miR-34a, hsa-miR-449a, hsa-miR-34c, hsa-miR-449b, hsa-miR-33a, hsa-miR-542, hsa-miR-449b, hsa-miR-145 and hsa-miR-212. For example, low miR-449a expression was found to predict a poorer prognosis via regulation of the expression of the target gene HDAC1 in colorectal cancer ([@b54-mmr-22-02-0620]). miR-34a/b/c were found to suppress intestinal tumorigenesis resulting from loss of Apc which downregulates the expression of a large number of protumorigenic factors ([@b55-mmr-22-02-0620]). In addition, miR-145 may serve as a tumor suppressor that downregulates hypoxia-inducible factor 1 and vascular endothelial growth factor expression via targeting of p70S6K1, which results in the inhibition of tumor growth and angiogenesis ([@b56-mmr-22-02-0620]).

In the present study, Kaplan-Meier analysis indicated that hub genes, including *FURIN, NFAT5, RBM12B, RRAGD* and *WIPI2*, were closely associated with the overall survival of patients with colon cancer. In a variety of cancer types and human cancer cell lines, high expression of *FURIN* was found to be positively associated with the high invasiveness of tumors, and it has been proposed as a marker of advanced or malignant tumors ([@b57-mmr-22-02-0620]). In addition, high expression of *FURIN* has been revealed to predict decreased survival in several human cancer types ([@b58-mmr-22-02-0620]). *NFAT5* is activated at multiple levels, and the activation is required for the induction of S100A4 in colon cancer cells ([@b59-mmr-22-02-0620]). In addition, *NFAT5* is upregulated in invasive human ductal breast carcinomas and has been demonstrated to participate in promoting carcinoma invasiveness using cell lines derived from human breast and colon carcinomas ([@b60-mmr-22-02-0620]). A previous study reported that *RBM12B* was associated with both breast cancer incidence and outcome ([@b61-mmr-22-02-0620]). However, there are few reports on the function of *RBM12B* in colon cancer. The present study indicated that high expression of *RBM12B* was associated with poor overall survival in patients with colon cancer. Thus, the role of *RBM12B* in the colon cancer requires further elucidation via more experimentation. *RRAGD* participates in a variety of molecular processes, improves the formation of breast cancer cell line cell-in-cell structure and may influence the late maturation of external cell vacuoles via regulation of mammalian target of rapamycin complex ([@b62-mmr-22-02-0620]). *WIPI2* is a mammalian effector of phosphatidylinositol 3-phosphate and is ubiquitously expressed in a variety of cell lines. *WIPI2* is recruited to early autophagosomal structures along with autophagy related 16 like 1 and ULK1 ([@b63-mmr-22-02-0620]). Autophagy influences cellular metabolism, the proteome and organelle numbers and quality. Dysfunctional autophagy contributes to multiple diseases, including cancer ([@b64-mmr-22-02-0620]). Currently, there is no report describing the effect of *WIPI2* on colon cancer via autophagy, which requires further investigation. The aforementioned research reveals that the ceRNA-associated hub genes identified in the present study serve an important role in the tumorigenesis and progression of colon cancer.

Among these lncRNAs and mRNAs closely associated with colon cancer survival, it was revealed that the lncRNA *MALAT1/miR-129-5p/NFAT5* axis may serve a vital role in the progression of colon cancer. Another study demonstrated that the *MALAT/mi-R203/DCP1A* axis is involved with the development and contributes to the malignancy of colorectal cancers ([@b65-mmr-22-02-0620]). This study may indicate that *MALAT1* may exert a regulating role by targeting small RNAs. However, the present study only used the GSE26334 dataset, and further *in vitro* and *in vivo* validation experiments are needed.

In the present study, a targeted drug for colon cancer was predicted using the 144 core genes in the colon cancer ceRNA network for the first time, to the best of the authors\' knowledge, which may represent a novel therapeutic target for the treatment of colon cancer. Furthermore, the drug was revealed to be a spleen tyrosine kinase inhibitor, and effective inhibition of B-cell receptor signal transduction *in vivo* results in a decrease in the proliferation and survival of malignant B cells and a significant prolongation of the survival time of treated animals ([@b66-mmr-22-02-0620]). In addition, this drug appears to represent a promising therapeutic for immunological diseases ([@b67-mmr-22-02-0620]). However, the use of the drug for the clinical treatment of colon cancer would still require further bioinformatic analysis and randomized controlled trials.
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![Association between expression of lncRNAs and prognosis in colon cancer. (A and C) Expression of lncRNAs metastasis-associated lung adenocarcinoma transcript (MALAT1) and maternally expressed gene 3 (MEG3) between normal and colon cancer tissues. (B and D) Kaplan-Meier analysis of the lncRNAs for the overall survival in the colon cancer patients. lncRNAs, long non-coding RNAs.](MMR-22-02-0620-g03){#f4-mmr-22-02-0620}

![Association between expression of mRNAs and prognosis in patients with colon cancer. (A) Expression level and (B) overall survival analysis of FURIN expression. (C) Expression level and (D) overall survival analysis of NFAT5 expression. (E) Expression level and (F) overall survival analysis of RBM12B expression. (G) Expression level and (H) overall survival analysis of RRAGD expression. (I) Expression level and (J) overall survival analysis of *WIPI2* expression. *FURIN*, Furin, FES upstream region; *NFAT5*, nuclear factor of activated T-cells 5; *RBM12B*, RNA binding motif protein 12B; *RRAGA*, Ras related GTP binding A; *WIPI2*, WD repeat domain phosphoinositide-interacting protein 2.](MMR-22-02-0620-g04){#f5-mmr-22-02-0620}

![Expression of lncRNA MALAT1, miR-129-5p and NFAT5 in LoVo colon cancer lines. lncRNA, long non-coding RNA; miRNA, microRNA; MALAT1, metastasis-associated lung adenocarcinoma transcript; NFAT5, nuclear factor of activated T-cells 5.](MMR-22-02-0620-g05){#f6-mmr-22-02-0620}

![Target set of core regulators and functional enrichment analysis of core genes. Functional enrichment map of (A) biological process, (B) cellular components and (C) molecular function GO terms for ceRNA network. (D) Enriched KEGG pathways for ceRNA network. GO, gene ontology; ceRNA, competing endogenous RNA; KEGG, Kyoto Encyclopedia of Genes and Genomes.](MMR-22-02-0620-g06){#f7-mmr-22-02-0620}

![The function enrichment and pathway analysis of 144 core genes in colon cancer. (A) Functional enrichment map of (A) biological process, (B) cellular components and (C) molecular function GO terms for ceRNA network. (D) Enriched KEGG pathways for ceRNA network. The gray area of the bar indicates that the P-value is not significant (P\>0.05). GO, gene ontology; ceRNA, competing endogenous RNA; KEGG, Kyoto Encyclopedia of Genes and Genomes.](MMR-22-02-0620-g07){#f8-mmr-22-02-0620}

![Targeting drug-gene network map based on 144 hub genes of colon adenocarcinoma.](MMR-22-02-0620-g08){#f9-mmr-22-02-0620}

###### 

Clinicopathological characteristics of all the 546 patients with colon cancer downloaded from TCGA.

  Clinical features   Patients n (%)
  ------------------- ----------------
  Age (years)         
    \>67              302 (55.31)
    ≤67               244 (44.69)
  Sex                 
    Male              284 (52.01)
    Female            262 (47.99)
  Pathology stage     
    I                 86 (15.75)
    II                219 (40.11)
    III               152 (27.84)
    IV                78 (14.29)
    Unknown           11 (2.01)
  Pathology M stage   
    M0                398 (72.89)
    M1                78 (14.29)
    MX                62 (11.36)
    Unknown           8 (1.47)
  Pathology N stage   
    N0                323 (59.16)
    N1                124 (22.71)
    N2                99 (18.13)
  Pathology T stage   
    T1                11 (2.01)
    T2                90 (16.48)
    T3                377 (69.05)
    T4                67 (12.27)
    TX                1 (0.18)

TCGA, The Cancer Genome Atlas.

###### 

Extracted lncRNA-miRNA-mRNA interaction pairs that require verification.

  lncRNA       mRNA        miRNA             R          P-value
  ------------ ----------- ----------------- ---------- -------------
  MALAT1       NFAT5       hsa-miR-142       0.41       7.6×10^−13^
  MALAT1       NFAT5       hsa-miR-384       0.41       7.6×10^−13^
  MALAT1       NFAT5       hsa-miR-519d      0.41       7.6×10^−13^
  MALAT1       NFAT5       hsa-miR-150       0.41       7.6×10^−13^
  MALAT1       NFAT5       hsa-miR-494       0.41       7.6×10^−13^
  MALAT1       NFAT5       hsa-miR-32        0.41       7.6×10^−13^
  MALAT1       NFAT5       hsa-miR-205       0.41       7.6×10^−13^
  MALAT1       NFAT5       hsa-miR-149       0.41       7.6×10^−13^
  MALAT1       NFAT5       hsa-miR-124       0.41       7.6×10^−13^
  **MALAT1**   **NFAT5**   **hsa-miR-129**   **0.41**   7.6×10^−13^
  MALAT1       RBM12B      hsa-miR-519d      0.32       6.6×10^−8^
  MALAT1       RBM12B      hsa-miR-200b      0.32       6.6×10^−8^
  MALAT1       RBM12B      hsa-miR-429       0.32       6.6×10^−8^
  MEG3         NFAT5       hsa-miR-215       0.26       2×10^−6^
  MEG3         NFAT5       hsa-miR-361       0.26       2×10^−6^
  MEG3         NFAT5       hsa-miR-122       0.26       2×10^−6^
  MEG3         NFAT5       hsa-miR-129       0.26       2×10^−6^
  MALAT1       ABCA1       hsa-miR-142       0.15       0.015
  MEG3         RRAGD       hsa-miR-129       0.14       0.011
  MALAT1       WIPI2       hsa-miR-383       0.13       0.026
  MALAT1       WIPI2       hsa-miR-503       0.13       0.026
  MALAT1       WIPI2       hsa-miR-1271      0.13       0.026
  MALAT1       WIPI2       hsa-miR-124       0.13       0.026
  MALAT1       RRAGD       hsa-miR-519d      0.043      0.48
  MALAT1       RRAGD       hsa-miR-144       0.043      0.48
  MALAT1       RRAGD       hsa-miR-124       0.043      0.48
  MALAT1       RRAGD       hsa-miR-129       0.043      0.48
  MALAT1       FURIN       hsa-miR-519d      0.042      0.49
  MALAT1       FURIN       hsa-miR-124       0.042      0.49

*The regulatory effect of lncRNA MALAT1/hsa-miR-129/NEAT5 axis (bold) in colon cancer could be verified in GSE26334. MALAT1*, metastasis-associated lung adenocarcinoma transcript; *MEG3*, maternally expressed gene 3; lnRNA, long non-coding RNA; miRNA, microRNA; *FURIN*, Furin, FES upstream region; *NFAT5*, nuclear factor of activated T-cells 5; *RBM12B*, RNA binding motif protein 12B; *RRAGA*, Ras related GTP binding A; *WIPI2*, WD repeat domain phosphoinositide-interacting protein 2; *ABCA1*, ATP-binding cassette subfamily A member 1.

###### 

Association between hub genes and targeted drugs in colon cancer (top 10).

  Drug      P-value                Connection
  --------- ---------------------- ------------
  DB12010   0.00672750878641727    8
  DB11638   0.0393484004831608     1
  DB01593   0.000357387058865982   0
  DB00142   0.010354570549436      0
  DB00114   0.0173304785268529     0
  DB00898   0.033077964206484      0
  DB00334   0.0376561578707151     0
  DB00543   0.042873010623447      0

DB12010 was revealed to be fostamatinib.

[^1]: Contributed equally
